Platform | Publications

Delivering on the RNA Revolution

Antibody Oligonucleotide Conjugates (AOC) therapeutics are designed to combine the proven technology of monoclonal antibodies (mAbs) with the precision and potency of oligonucleotide therapies to access previously untreatable tissue and cell types, opening new potential treatments for patients. We have done the experiments and have followed the data to build our AOC platform. We are revolutionizing the RNA therapeutics field by delivering oligonucleotides where they are needed – including beyond the liver.

Publications

January 5, 2017

Targeting Therapeutic Oligonucleotides

The New England Journal of Medicine
Levin, AA. N Engl J Med 2017;376:1DOI 10.1056/NEJMcibr1613559

January 5, 2017

Treating Disease at the RNA Level with Oligonucleotides

The New England Journal of Medicine
Levin, AA. N Engl J Med 2019;380:1DOI: 10.1056/NEJMra1705346

Platform | Publications

Publications

Targeting Therapeutic Oligonucleotides

Treating Disease at the RNA Level with Oligonucleotides

Presentations

2021 FSHD Society IRC Annual Meeting

2021 AAN Annual Meeting

2021 MDA Virtual Clinical and Scientific Conference